Advertisement

Supportive Care in Cancer

, Volume 16, Issue 11, pp 1291–1298 | Cite as

Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine

  • Eylem Sahin CankurtaranEmail author
  • Elvan Ozalp
  • Haldun Soygur
  • Derya Iren Akbiyik
  • Levent Turhan
  • Necati Alkis
Original Article

Abstract

Goals of the work

This study aimed to compare the effectiveness of mirtazapine and imipramine on not only the distressing symptoms of cancer patients such as pain, nausea, vomiting, appetite loss, and sleep disturbances but also depressive and anxiety symptoms.

Materials and methods

Fifty-three patients with cancer who were diagnosed with major depressive disorder, anxiety disorder, or adjustment disorder were included. Twenty patients on mirtazapine, 13 patients on imipramine, and 20 patients in the control group without medication were interviewed during three visits (baseline, third week, and sixth week). Pain, nausea, vomiting, appetite loss, and sleep disturbances were evaluated with self-assessment single-symptom scales during each visit. The patients were also asked to complete the Hospital Anxiety Depression Scale (HADS) during each visit.

Main results

There were no significant differences among the three visits in the mirtazapine, imipramine, or control groups in terms of pain, nausea, vomiting, or appetite loss. For the initial, middle, and late insomnia, only the mirtazapine group showed improvements (p = 0.001, p = 0.001, p = 0.003). There were also significant differences in the mean total (p = 0.03), anxiety (p = 0.003), and depression (p = 0.025) scores of HADS among the three visits for patients taking mirtazapine. There were no significant differences for HADS scores from the baseline to the end point for patients taking imipramine or control group patients.

Conclusion

Our findings suggest that mirtazapine is effective for resolving insomnia as well as anxiety and depressive symptoms in cancer patients. However, more systematic research, such as placebo-controlled studies, is needed.

Keywords

Cancer Distressing symptoms of cancer Imipramine Mirtazapine 

References

  1. 1.
    Aapro M, Blower P (2005) 5-Hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dosage of administered agents. Cancer 104(1):1–18 (Jul 1)PubMedCrossRefGoogle Scholar
  2. 2.
    Akdemir A, Örsel S, Dağ I (1996) The reliability and validity of Hamilton Depression Rating Scale. The Journal of Psychiatry, Psychology and Psychopharmacology 4(4):251–259 (in Turkish)Google Scholar
  3. 3.
    Anttila SAK, Leinonen EVJ (2001) A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7(3):249–264PubMedCrossRefGoogle Scholar
  4. 4.
    Aydemir Ö, Güvenir T, Küey L, Kültür S (1997) The reliability and validity of Turkish form of hospital anxiety and depression scale. Journal of Turkish Psychiatry 8:280–287 (in Turkish)Google Scholar
  5. 5.
    Breitbart W, Payne DK (1998) Pain. In: Holland JC (ed) Psyco-oncology. Oxford University Press, New York, pp 450–468 (chapter 38)Google Scholar
  6. 6.
    Bruijn JA, Moleman P, Mulder PG, van den Broek WW (1999) Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry 32(3):87–92 (May)PubMedGoogle Scholar
  7. 7.
    Bruijn JA, Moleman P, Mulder PG, van den Broek WW, van Hulst AM, van der Mast RC, van de Wetering BJ (1996) A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology (Berl) 127(3):231–237 (Oct)CrossRefGoogle Scholar
  8. 8.
    Caraceni A, Cheville A, Portenoy RK (2000) Pain management: pharmacological and non-pharmacological treatments. In: Massie MJ (ed) Pain: what psychiatrists need to know. American Psychiatric Press Inc., Washington, DC, pp 23–69 (chapter 2)Google Scholar
  9. 9.
    Derogatis LR, Morrow GR, Fetting J, Penman D, Piasetsky S, Schmale AM (1983) The prevalence of psychiatric disorders among cancer patients. JAMA 249:751–757PubMedCrossRefGoogle Scholar
  10. 10.
    Elliot AJ, Roy-Byrne PP (2000) Mirtazapine for depression in patients with HIV. J Clin Psychopharmacol 20:265–267CrossRefGoogle Scholar
  11. 11.
    Fawcett J, Barkin RL (1998) Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine fort he treatment of patients with major depression. J Affect Disord 51:267–285PubMedCrossRefGoogle Scholar
  12. 12.
    First MB, Spitzer RL, Gibbon M (1997) Structured clinical interview for DSM-IV clinical version (SCID- I/CV). American Psychiatric Press, Washington, DCGoogle Scholar
  13. 13.
    Fleishman SB (1998) Cancer cachexia. In: Holland JC (ed) Psyco-oncology. Oxford University Press, New York, pp 468–476 (chapter 38)Google Scholar
  14. 14.
    Freynhagen R, Muth-Selbach U, Lipfert P, Stevens MF, Zacharowski K, Tölle TR (2006) The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 22(2):257–264PubMedCrossRefGoogle Scholar
  15. 15.
    Gorman JM (1999) Mirtazapine: a clinical overview. J Clin Psychiatry 60(suppl 17):9–13PubMedGoogle Scholar
  16. 16.
    Grunberg SM, Srivastava A, Grunberg KJ, Weeks J (2002) Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score. Support Care Cancer 10(8):624–629 (Nov)PubMedCrossRefGoogle Scholar
  17. 17.
    Gupta D, Lis CG, Grutsch JF (2007) The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer. Journal of Pain and Symptom Management 34(1):40–47 (Jul)PubMedCrossRefGoogle Scholar
  18. 18.
    Hundley JL, Yosipovitch GJ (2004) Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. Am Acad Dermatol 50(6):889–891 (Jun)CrossRefGoogle Scholar
  19. 19.
    Jackson KC, St Onge El (2003) Antidepressant pharmacotherapy: considerations for the pain clinician. Pain Pract 3(2):135–143 (Jun)PubMedCrossRefGoogle Scholar
  20. 20.
    Kast RE (2001) Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 9:469–470PubMedCrossRefGoogle Scholar
  21. 21.
    Kast RE, Foley KF (2007) Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care(Engl) 16(4):351–354 (Jul)CrossRefGoogle Scholar
  22. 22.
    Massie MJ, Popkin MK (1998) Depressive disorder. In: Holland JC (ed) Psyco-oncology. Oxford University Press, New York, pp 518–541 (chapter 45)Google Scholar
  23. 23.
    Montgomery SA (1995) Safety of mirtazapine: a review. Int Clin Psychopharmacol 10(suppl 4):37–45PubMedCrossRefGoogle Scholar
  24. 24.
    Mystakidou K, Parpa E, Tsilika E, Pathiaki M, Gennatas K, Smyrniotis V, Vassiliou I (2007) The relationship of subjective sleep quality, pain, and quality of life in advanced cancer patients. Sleep 30(6):737–742 (Jun 1)PubMedGoogle Scholar
  25. 25.
    Ozkurkçugil A, Aydemir O, Yıldız M (1999) The reliability study of structured clinical interview for DSM-IV clinical version (SCID-I/CV). Journal of Drug and Treatment 12:233–236 (in Turkish)Google Scholar
  26. 26.
    Potash M, Breitbart W (2002) Affective disorders in advanced cancer. Hematol Oncol Clin North Am 16:671–700PubMedCrossRefGoogle Scholar
  27. 27.
    Raji MA, Barnum PD, Freeman J, Markowitz AB (2007) Mirtazapine for depression and comorbidities in older patients with cancer. Ann Pharmacother 41(9):1548–1549 (Sep)PubMedGoogle Scholar
  28. 28.
    Raji MA, Brady SR (2001) Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Ann Pharmacother 35(9):1024–1027 (Sep)PubMedCrossRefGoogle Scholar
  29. 29.
    Sitsen JMA, Zivkov M (1995) Mirtazapine: clinical profile. CNS Drugs 4(Suppl 4):39–48CrossRefGoogle Scholar
  30. 30.
    Steifel FC, Breitbart WS, Holland JC (1989) Corticosteriods in cancer, neuropsychiatric complications. Cancer Invest 7(5):479–491CrossRefGoogle Scholar
  31. 31.
    Szegedi A, Schwertfeger A (2005) Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin Pharmacother 6(4):631–641PubMedCrossRefGoogle Scholar
  32. 32.
    Taylor DJ, Mallory LJ, Lichstein KL, Durrence HH, Riedel BW, Bush AJ (2007) Comorbidity of chronic insomnia with medical problems. Sleep 30(2):213–218 (Feb 1)PubMedGoogle Scholar
  33. 33.
    Theobald DE (2000) A patient with B-cell lymphoma and major depression treated with mirtazapine. Primary Care & Depression and Anxiety 20(8):61–63 (September)Google Scholar
  34. 34.
    Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD (2002) An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. Journal of Pain and Symptom Management 23:442–447PubMedCrossRefGoogle Scholar
  35. 35.
    Thomas SG (2000) Irritable bowel syndrome and mirtazapine. Am J Psychiatry 157:1341–1342PubMedCrossRefGoogle Scholar
  36. 36.
    Thompson DS (2000) Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 41:356–359PubMedCrossRefGoogle Scholar
  37. 37.
    Van Gool AR, Bannink M, Stronks DL, Vos MS (2003) Mirtazapine in cancer patients. Journal of Pain and Symptom Management 25(1):7–8PubMedCrossRefGoogle Scholar
  38. 38.
    Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15):1549–1563PubMedCrossRefGoogle Scholar
  39. 39.
    Williamss BW (1978) A structured interview guide for Hamilton Depression Rating Scale. Arch Gen Psychiatry 45:742–747Google Scholar
  40. 40.
    Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370 (Jun)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Eylem Sahin Cankurtaran
    • 1
    • 2
    Email author
  • Elvan Ozalp
    • 1
  • Haldun Soygur
    • 1
  • Derya Iren Akbiyik
    • 1
  • Levent Turhan
    • 1
  • Necati Alkis
    • 1
  1. 1.Ankara Oncology Training and Research HospitalPsychiatry ClinicAnkaraTurkey
  2. 2.Ankara Oncology Research and Training Hospital (Division of Ahmet Andicen Hospital)Clinic of PsychiatryAnkaraTurkey

Personalised recommendations